Core Viewpoint - Weigao Blood Purification (603014.SH) reported a positive performance in the first half of 2025, with revenue and net profit showing growth compared to the previous year [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.765 billion yuan, representing a year-on-year increase of 8.52% [1] - The net profit attributable to shareholders was around 220 million yuan, reflecting a year-on-year growth of 10.11% [1] - Research and development expenses amounted to approximately 70.18 million yuan, accounting for 3.98% of total revenue [1] Dividend Distribution - The company plans to distribute a cash dividend of 1.6 yuan (including tax) for every 10 shares to all shareholders [1] Product and Market Presence - As of the end of the reporting period, Weigao Blood Purification held 16 Class III medical device product registration certificates [1] - The company's products are sold across 31 provinces, municipalities, and autonomous regions in China, reaching over 6,000 medical institutions, including more than 1,000 tertiary hospitals [1]
威高血净上半年营收利润双增长